Korean biotech making peptide-based ingredients used in cosmeceuticals and skincare products sold under partner K-beauty brands.
Korean biotech making peptide-based ingredients used in cosmeceuticals and skincare products sold under partner K-beauty brands.
Moat: narrow (IP / patents, process know-how). Peptide synthesis patents and formulation know-how used across many partner skincare brands.
Headquarters: Anyang, South Korea · Founded: 2000 · Employees: 201
Size Caregen (214370.KS) is a South Korea Materials company (Chemicals: Major Diversified) with a market value of $982M, the 241st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩26,600 on 18 Nov 2026.
Performance Over six months the shares fell 73.9%, against -24.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 2.1% over the last twelve months (peer median +5.8%); the operating margin is 20.3% (peer median 10.4%).
Valuation It trades at 21.5× forward earnings against a peer median of 21.7× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points below its cost of capital (7.9% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩76.2B | ₩72.8B | ₩82.6B | ₩79.2B | ₩69.1B |
| Revenue growth | — | -12% | +4% | +15% | — |
| Gross profit | ₩48.6B | ₩50.0B | ₩53.0B | ₩56.8B | ₩50.7B |
| EBITDA | ₩20.6B | ₩25.6B | ₩39.2B | ₩44.6B | ₩35.7B |
| Net income | ₩13.4B | ₩20.1B | ₩32.3B | ₩39.9B | ₩27.3B |
| Free cash flow | ₩24.6B | ₩14.7B | -₩52.4B | ₩20.4B | ₩29.6B |
| Capital expenditure | ₩2.71B | ₩4.92B | ₩67.0B | ₩9.70B | ₩3.03B |
| Total debt | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Caregen 214370.KS | $982M | -74% | -2% | 20% | 21.5× | 36.8% |
| PharmaResearch 214450.KS | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% |
| Kolmar Korea 161890.KS | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% |
| Cosmax 192820.KS | $2.51B | +53% | +25% | 8% | 18.8× | n/a |
| Croda International CRDA.L | $7.07B | +29% | +3% | 16% | 24.2× | 21.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214370.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.7% | -13.1% | 3rd lowest of 21 |
| 6-month return | -73.9% | -24.0% | lowest of 21 |
| Distance from 52-week high | -82.7% | -46.0% | lowest of 21 |
| Revenue growth (TTM) | -2.1% | +5.8% | 7th lowest of 21 |
| Operating margin | 20.3% | 10.4% | 3rd highest of 21 |
| Forward P/E | 21.5× | 21.7× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 36.8% | 7.1% | most demanding of 12 |
| Growth delivered (Del g) | +3.8% | +3.9% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | +33.0 pp | -2.4 pp | most demanding of 12 |
| ROIC minus cost of capital | -1.6 pp | -2.2 pp | 10th highest of 21 |
| EV / EBITDA | 61.8× | 9.8× | 2nd most expensive of 8 |
| Net debt / EBITDA | -1.4× | 0.7× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caregen 214370.KS | South Korea | $982M | -74% | -2% | 20% | 21.5× | 36.8% | +3.8% |
| Dalian Bio-Chem 603360.SS | China | $971M | -54% | 0% | 16% | 21.7× | 8.5% | +18.4% |
| Jubilant Ingrevia JUBLINGREA.NS | India | $1.00B | -19% | +15% | 10% | 21.6× | 28.0% | +44.9% |
| Raghav Productivity Enhancers RPEL.NS | India | $942M | +109% | +38% | 28% | n/a | n/a | n/a |
| Metis TechBio 7666.HK | Hong Kong | $1.05B | -64% | +6,987% | -367% | n/a | n/a | n/a |
| Jiangsu Zhengdan Chemical Industry 300641.SZ | China | $914M | -29% | -30% | 17% | n/a | 7.1% | +11.6% |
| Victrex VCT.L | United Kingdom | $1.06B | +46% | -1% | 14% | 22.5× | 16.7% | +1.9% |
| Zhejiang Huangma Technology 603181.SS | China | $891M | -33% | +7% | 17% | 13.8× | n/a | n/a |
| Qingdao Huicheng Environmental Technology 300779.SZ | China | $1.08B | -48% | -13% | 5% | 69.5× | n/a | n/a |
| Shanghai Emperor of Cleaning Hi-Tech 603200.SS | China | $1.12B | -24% | +4% | -8% | n/a | n/a | n/a |
| CNSIG Inner Mongolia Chemical Industry 600328.SS | China | $1.12B | -36% | -20% | -7% | n/a | n/a | n/a |
| Jinan Acetate Chemical 4763.TW | Taiwan | $1.14B | -5% | -24% | 43% | 6.6× | -20.2% | +41.2% |
| Hubei Jianghan New Materials 603281.SS | China | $1.15B | -38% | +8% | 17% | 21.1× | 3.9% | +6.3% |
| Guangzhou Sanfu Newmaterials Technology 688359.SS | China | $832M | -54% | +8% | -7% | n/a | n/a | n/a |
| Lanxess LXS.DE | Germany | $1.19B | -24% | -4% | 0% | n/a | 5.3% | -1.5% |
| Jilin Chemical Fibre Stock 000420.SZ | China | $1.20B | -34% | +11% | 5% | 130.4× | n/a | n/a |
| Xinyaqiang Silicon Chemistry 603155.SS | China | $798M | -15% | +25% | 12% | 37.4× | 22.5% | +3.9% |
| Sanyo Chemical Industries 4471.T | Japan | $794M | +8% | +8% | 11% | 9.6× | -7.2% | -2.5% |
| Suzhou Highfine Biotech 301393.SZ | China | $786M | -15% | +36% | 17% | 29.4× | n/a | n/a |
| Jiangsu Shuangxing Color Plastic New Materials 002585.SZ | China | $1.27B | -10% | -4% | -4% | 57.9× | 21.0% | +0.2% |
| Nippon Soda 4041.T | Japan | $1.29B | +11% | 0% | 10% | 12.2× | 5.2% | +1.8% |